Shares of Scholar Rock (SRRK) tumbled Tuesday after the Food and Drug Administration rejected the company's spinal muscular atrophy drug, citing concerns at the Catalent fill-finish facility in Indiana. Fill finish is the final manufacturing step for some drugs, involving filling drug substances into final containers, like vials and syringes. FDA inspectors found some problems during a regular inspection of the Catalent facility, which Novo Nordisk (NVO) owns, in December 2024. Wedbush analyst David Nierengarten said Catalent responded to the FDA in August. The rejection likely sets Scholar Rock's apitegromab...
Related Coverage
AllSides Picks
Headline Roundup
Jensen Huang's Reported Ties to Suspected Chinese Spy Draw Scrutiny Over National Security
November 12th, 2026
Headline Roundup
Nvidia CEO Jensen Huang Resigns
November 11th, 2026
Story of the Week
Jensen Huang Resigns from Nvidia
AllSides
November 12th, 2026
Recommended Reading
Can Technology Help Repair Our Divided Democracy?
John Gable, AllSides Co-founder
October 19th, 2026